Observational study of quantiferon®-TB gold in-tube assay in tuberculosis contacts in a low incidence area

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Bergot, Emmanuel ^a,b   Haustraete, Eglantine ^a   Malbruny, Brigitte ^a   Magnier, Romain ^a   Salaün, Marie Anne ^b   Zalcman, Gérard ^a  

^a CAEN UNIVERSITY HOSPITAL   (France)

^b Centre de Prévention des Maladies Infectieuses   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; ISONIAZID; ISONIAZID PLUS RIFAMPICIN;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BACTERIUM CULTURE; BIOASSAY; CHEMOPROPHYLAXIS; CHILD; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE COURSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; INFANT; INFECTION PREVENTION; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OBSERVATIONAL STUDY; PATIENT ASSESSMENT; PREDICTIVE VALUE; SCHOOL CHILD; SKIN INDURATION; TREATMENT CONTRAINDICATION; TREATMENT REFUSAL; TUBERCULIN TEST; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TUBERCULIN TEST; TUBERCULOSIS; YOUNG ADULT;

EID: 84866613737     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0043520     Document Type: Article

References (28)

1. American Thoracic Society: Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 161: s221-247.
2. Erkens CG, Kamphorst M, Abubakar I, Bothamley GH, Chemtob D, et al. (2010) Tuberculosis contact investigation in low prevalence countries: a European consensus. Eur Respir J 36: 925-949.
3. [Intradermal reaction to tuberculin (IDR) or tuberculin test]. Rev Mal Respir 20: S27-33.
4. Wang L, Turner MO, Elwood RK, Schulzer M, FitzGerald JM, (2002) A meta-analysis of the effect of Bacille Calmette Guerin vaccination on tuberculin skin test measurements. Thorax 57: 804-809.
5. Diel R, Goletti D, Ferrara G, Bothamley G, Cirillo D, et al. (2011) Interferon-gamma release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. Eur Respir J 37: 88-99.
6. Kik SV, Franken WP, Arend SM, Mensen M, Cobelens FG, et al. (2009) Interferon-gamma release assays in immigrant contacts and effect of remote exposure to Mycobacterium tuberculosis. Int J Tuberc Lung Dis 13: 820-828.
7. Arend SM, Thijsen SF, Leyten EM, Bouwman JJ, Franken WP, et al. (2007) Comparison of two interferon-gamma assays and tuberculin skin test for tracing tuberculosis contacts. Am J Respir Crit Care Med 175: 618-627.
8. Diel R, Loddenkemper R, Meywald-Walter K, Niemann S, Nienhaus A, (2008) Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis. Am J Respir Crit Care Med 177: 1164-1170.
9. Kik SV, Franken WP, Mensen M, Cobelens FG, Kamphorst M, et al. (2010) Predictive value for progression to tuberculosis by IGRA and TST in immigrant contacts. The European respiratory journal: official journal of the European Society for Clinical Respiratory Physiology 35: 1346-1353.
10. Diel R, Loddenkemper R, Niemann S, Meywald-Walter K, Nienhaus A, (2011) Negative and Positive Predictive Value of a Whole-Blood Interferon-{gamma} Release Assay for Developing Active Tuberculosis: An Update. Am J Respir Crit Care Med 183: 88-95.
11. Diel R, Wrighton-Smith P, Zellweger JP, (2007) Cost-effectiveness of interferon-gamma release assay testing for the treatment of latent tuberculosis. Eur Respir J 30: 321-332.
12. Deuffic-Burban S, Atsou K, Viget N, Melliez H, Bouvet E, et al. (2010) Cost-effectiveness of QuantiFERON-TB test vs. tuberculin skin test in the diagnosis of latent tuberculosis infection. Int J Tuberc Lung Dis 14: 471-481.
13. Mesure de la couverture vaccinale en France. Bilan des outils et des méthodes en l'an 2000. Institut de veille sanitaire. 1-57 p., (2001)
14. Enquête autour d'un cas cas. Recommandations pratiques.
15. [HAS evaluation: interferon gamma detection test for the diagnosis of tuberculous infections]. Med Mal Infect 37: 689-693.
16. Diel R, Loddenkemper R, Nienhaus A, (2012) Predictive value of interferon-gamma release assays and tuberculin skin testing for predicting progression from latent TB infection to disease state: a meta-analysis. Chest.
17. Rangaka MX, Wilkinson KA, Glynn JR, Ling D, Menzies D, et al. (2012) Predictive value of interferon-gamma release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 12: 45-55.
18. Bradshaw L, Davies E, Devine M, Flanagan P, Kelly P, et al. (2011) The role of the interferon gamma release assay in assessing recent tuberculosis transmission in a hospital incident. PLoS One 6: e20770.
19. Gershon AS, McGeer A, Bayoumi AM, Raboud J, Yang J, (2004) Health care workers and the initiation of treatment for latent tuberculosis infection. Clin Infect Dis 39: 667-672.
20. Martinez Alfaro E, Solera J, Serna E, Cuenca D, Castillejos ML, et al. (1998) [Compliance, tolerance and effectiveness of a short chemoprophylaxis regimen for the treatment of tuberculosis]. Med Clin (Barc) 111: 401-404.
21. LoBue PA, Moser KS, (2003) Use of isoniazid for latent tuberculosis infection in a public health clinic. Am J Respir Crit Care Med 168: 443-447.
22. Menzies D, Dion MJ, Rabinovitch B, Mannix S, Brassard P, et al. (2004) Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. Am J Respir Crit Care Med 170: 445-449.
23. Menzies D, Long R, Trajman A, Dion MJ, Yang J, et al. (2008) Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial. Ann Intern Med 149: 689-697.
24. Page KR, Sifakis F, Montes de Oca R, Cronin WA, Doherty MC, et al. (2006) Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study. Arch Intern Med 166: 1863-1870.
25. Figoni J AD, Che D, (2011) Tuberculosis cases notified in France. Bulletin Epidemiologique Hebdomadaire 22: 258-260.
26. van Zyl-Smit RN, Zwerling A, Dheda K, Pai M, (2009) Within-subject variability of interferon-g assay results for tuberculosis and boosting effect of tuberculin skin testing: a systematic review. PLoS One 4: e8517.
27. van Zyl-Smit RN, Pai M, Peprah K, Meldau R, Kieck J, et al. (2009) Within-subject variability and boosting of T-cell interferon-gamma responses after tuberculin skin testing. Am J Respir Crit Care Med 180: 49-58.
28. Sauzullo I, Massetti AP, Mengoni F, Rossi R, Lichtner M, et al. (2011) Influence of previous tuberculin skin test on serial IFN-gamma release assays. Tuberculosis (Edinb) 91: 322-326.